RecruitingPhase 2NCT06433609

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Sponsor

Beijing GoBroad Hospital

Enrollment

113 participants

Start Date

Aug 5, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Breast Cancer

Summary

Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102 combined with adebrelimab in HER2-negative advanced breast cancer.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adebrelimab, a drug called SHR-A1811, and others for people with advanced breast cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.